Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$824M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$459M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
| 4 |
Warner Bros
WBD
|
+$287M |
| 5 |
Tesla
TSLA
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.88B |
| 2 |
AT&T
T
|
+$530M |
| 3 |
Meta Platforms (Facebook)
META
|
+$481M |
| 4 |
Workday
WDAY
|
+$462M |
| 5 |
Apple
AAPL
|
+$354M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 92.22% |
| 2 | Technology | 1.79% |
| 3 | Consumer Discretionary | 1.52% |
| 4 | Communication Services | 1.04% |
| 5 | Financials | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZY
11926
PUT
DELISTED
Zymergen Inc. Common Stock
ZY
| $48K | ﹤0.01% |
39,200
-19,200
| -33% | -$32.2K |
|
11927
PUT
Acumen Pharmaceuticals
ABOS
$219M
| $47K | ﹤0.01% |
+10,100
| New | +$37.9K |
|
11928
PUT
American Coastal Insurance
ACIC
$446M
| $47K | ﹤0.01% |
+29,900
| New | +$63.4K |
|
11929
CALL
Anixa Biosciences
ANIX
$122M
| $47K | ﹤0.01% |
15,400
-8,700
| -36% | -$27.4K |
|
|
AUTL
11930
Autolus Therapeutics
AUTL
$628M
| $47K | ﹤0.01% |
+16,617
| New | +$50.6K |
|
11931
CPS Technologies
CPSH
$76M
| $47K | ﹤0.01% |
15,566
-28,181
| -64% | -$105K |
|
11932
PUT
Entravision Communication
EVC
$747M
| $47K | ﹤0.01% |
10,300
-16,700
| -62% | -$85.7K |
|
11933
CALL
iBio
IBIO
$69.5M
| $47K | ﹤0.01% |
362
-93
| -20% | -$14K |
|
11934
Inuvo
INUV
$12M
| $47K | ﹤0.01% |
9,483
+7,484
| +374% | +$33.3K |
|
11935
Protara Therapeutics
TARA
$236M
| $47K | ﹤0.01% |
15,969
+2,230
| +16% | +$8.15K |
|
11936
PUT
Arq
ARQ
$96.1M
| $47K | ﹤0.01% |
+10,100
| New | +$55K |
|
11937
PUT
Q32 Bio
QTTB
$481M
| $47K | ﹤0.01% |
1,333
-1,017
| -43% | -$34.7K |
|
|
TCON
11938
PUT
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $47K | ﹤0.01% |
1,175
-50
| -4% | -$1.94K |
|
|
BGRY
11939
PUT
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $47K | ﹤0.01% |
32,600
-5,300
| -14% | -$11.7K |
|
|
WEJO
11940
DELISTED
Wejo Group Limited Common Shares
WEJO
| $47K | ﹤0.01% |
39,198
-89,881
| -70% | -$210K |
|
|
ENDP
11941
CALL
DELISTED
Endo International plc
ENDP
| $47K | ﹤0.01% |
99,200
-68,800
| -41% | -$87.4K |
|
|
LJPC
11942
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $47K | ﹤0.01% |
14,800
-7,800
| -35% | -$30.4K |
|
11943
CALL
Alzamend Neuro
ALZN
$8.06M
| $46K | ﹤0.01% |
40
+26
| +186% | +$33.7K |
|
11944
Aprea Therapeutics
APRE
$10.8M
| $46K | ﹤0.01% |
3,098
-2,470
| -44% | -$56.9K |
|
11945
PUT
Broadwind
BWEN
$109M
| $46K | ﹤0.01% |
28,100
-71,400
| -72% | -$128K |
|
11946
Data I/O
DAIO
$31M
| $46K | ﹤0.01% |
15,017
-9,926
| -40% | -$32.8K |
|
11947
Good Times Restaurants
GTIM
$15.8M
| $46K | ﹤0.01% |
+15,237
| New | +$46.8K |
|
|
MESO
11948
CALL
Mesoblast
MESO
$2.36B
| $46K | ﹤0.01% |
10,350
-17,650
| -63% | -$121K |
|
|
TALK
11949
CALL
DELISTED
Talkspace
TALK
| $46K | ﹤0.01% |
26,900
+600
| +2% | +$901 |
|
11950
Zevia
ZVIA
$102M
| $46K | ﹤0.01% |
+16,217
| New | +$50.2K |
|
Similar funds
Jeff Yass's Q2 2022 Portfolio in Review
As of Q2 2022, Jeff Yass held 14,668 positions worth $404B, down 30% from $578B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Jeff Yass's Q2 2022 filing shows 1,801 new, 4,898 increased, 5,771 reduced and 1,897 closed positions. Its largest new stake was iShares US Treasury Bond ETF: 1,544,259 shares worth $36.9M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.88B.
By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 92% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q2 2022 buy was iShares US Treasury Bond ETF: 1,544,259 shares worth $36.9M.
- Jeff Yass added most to Amazon in Q2 2022, an estimated $824M increase.
- Jeff Yass's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.88B.
- Jeff Yass fully exited Discovery, Inc. Series C Common Stock in Q2 2022, selling an estimated $176M.
- Jeff Yass's ten largest holdings make up 32% of its $404B portfolio in Q2 2022.
- Jeff Yass opened 1,801 new positions and closed 1,897 in Q2 2022.
- Jeff Yass's portfolio value fell 30% quarter-over-quarter to $404B.
Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.